Investment Rating - The report maintains an "Outperform" rating for the company with a target price of $10.28, while the current price is $3.74 [2][6]. Core Views - The company is facing seasonal pressures in Q3, but confidence in the FY25 growth target remains unchanged. The report anticipates a significant revenue increase in Q4 due to the release of pent-up consumer demand [4][5]. - The company’s offline medical beauty segment has shown strong growth, with revenue increasing by 427% year-on-year to 1.444 billion RMB in Q2, exceeding management's guidance [3][4]. - Despite a projected increase in revenue for FY25, the company is expected to incur a larger loss than previously forecasted, with losses now estimated to exceed 140 million RMB [5][6]. Financial Summary - For FY25, the company is projected to generate revenue of 1.546 billion RMB, reflecting a 5% increase from the previous year, while FY26 revenue is expected to rise significantly to 2.545 billion RMB, a 65% increase [2][9]. - The net profit for FY25 is forecasted to be a loss of 140 million RMB, with a projected recovery to a profit of 11 million RMB in FY26 [2][9]. - The gross margin is expected to decline to 49.3% in FY25 and further to 42.5% in FY26, indicating pressure on profitability [2][9]. Business Segment Insights - The offline medical beauty segment is expected to see Q3 revenue of 1.7 billion RMB, a 274% increase year-on-year, with a significant ramp-up anticipated in Q4 [4]. - The upstream product sales are projected to decline by 16% for FY25, while the POP business is expected to see a 38% decrease in revenue for the same period [4][5]. - The report highlights the company's strategy to open 10 new offline stores, despite the anticipated seasonal slowdown [4].

Investment Rating - The report initiates coverage with an OUTPERFORM rating for the company, with a target price of $10.10, compared to the current price of $5.87 [3][4]. Core Insights - The company is positioned in the burgeoning light medical aesthetics industry in China, benefiting from increasing consumer demand for beauty and anti-aging solutions, a diverse range of upstream products, and improving industry standards and transparency [4][5]. - Despite a significant stock price increase of 487% since mid-June, the company is expected to continue its upward trajectory due to rapid expansion and substantial growth potential [4][6]. Company Overview - The company, So-Young (SY US), is a leading medical aesthetics service group in China and the first online medical aesthetics service platform listed on NASDAQ, established in 2013 [10]. - As of January 2024, the platform has onboarded 57,464 certified institutions and 43,771 physicians, with over 630 million beauty diaries and 210 million downloads [10][11]. Market Overview - The light medical aesthetics market in China is projected to grow at a CAGR of 16.3%, reaching RMB 339 billion by 2030, driven by increased consumer awareness and a diverse product supply [5][32]. - The market remains highly fragmented, with a significant opportunity for chain institutions to increase their penetration due to the standardized nature of light medical aesthetics projects [5][41]. Competitive Advantages - The company aims to address industry pain points such as information asymmetry and high customer acquisition costs through its supply chain advantages and digital marketing capabilities [6][47]. - The rapid expansion of the company's clinics, from 1 in May 2023 to 32 by mid-2025, showcases its strong execution capabilities and ambition to reach 1,000 clinics in the next 7-8 years [6][58]. Financial Analysis and Forecast - Revenue is projected to grow from RMB 1.47 billion in 2024 to RMB 2.68 billion in 2026, with a significant increase in net profit expected in 2026 [3][4]. - The company’s traditional POP business is expected to stabilize, contributing positive cash flow, while the medical aesthetics segment is anticipated to become a new growth driver [7][12]. Valuation and Recommendations - The report employs a segmented valuation approach, assigning different P/E ratios to various business segments, resulting in a target price of $10.10 [7][4]. - The company is expected to maintain a competitive edge through its cost-effective operations and strong digital capabilities, with a projected net profit margin improvement to 20% in the future [7][78].

Summary of the Conference Call for Xinyang Company Overview - Xinyang has an estimated valuation of approximately 800 million RMB after acquiring Jizhi Laser and is acting as an agent for 11 Korean hyaluronic acid products. The company operates 32 Xinyang Youth Clinics and plans to expand to 50 clinics by the end of 2025, focusing on franchise openings in second and third-tier cities [2][3][10]. Industry Insights - The non-surgical segment of China's light medical beauty market has reached 70%-80% market share, with intense competition in the hyaluronic acid market. Xinyang effectively controls customer acquisition costs, averaging 600 RMB, significantly lower than traditional medical beauty institutions [2][4][7]. - The light medical beauty market is expected to see over 2,000 institutions in China, based on the penetration rate observed in South Korea [5]. Financial Performance - Xinyang's total revenue for 2023 and 2024 is projected to be around 1.5 billion RMB, with chain revenue of 170 million RMB in 2024 and nearly 100 million RMB in Q1 2025. The company anticipates achieving profitability in Q4 2025 [4][10][25]. Business Model and Expansion Strategy - Xinyang's business model consists of three main segments: an internet platform (Xinyang APP), upstream products (including the acquisition of Jizhi Laser), and downstream light medical beauty chain brand Xinyang Youth Clinics [3][4]. - The company plans to open 50 new clinics by the end of 2025, with a focus on second and third-tier cities, and aims to maintain a rapid expansion pace [20][31]. Operational Efficiency - Xinyang has streamlined its SKU offerings, focusing on standardized projects like phototherapy and anti-aging injections, which enhances operational efficiency [2][13]. - The average customer acquisition cost is only 600 RMB, compared to 30%-50% of total costs for traditional medical beauty institutions [7][15]. Product Development and Supply Chain - Xinyang is set to launch new water light and picosecond devices in the second half of 2025, with plans for new generation products in 2026-2027 [8][16]. - The company has invested significantly in supply chain management, securing exclusive rights to upstream manufacturers, which allows for better pricing and cost control [16][27]. Competitive Advantages - Xinyang's advantages over competitors include a strong internet platform, proprietary products, and a robust team of professional doctors, which enhance cost-effectiveness and market competitiveness [11][19]. - The company believes that the entry of giants like JD Health into the medical beauty sector will not pose significant competitive pressure due to their lack of brand recognition and medical resources [23]. Customer Retention and Marketing - Xinyang employs private domain operations and pricing advantages to enhance user satisfaction and acquisition effectiveness, with a significant portion of customer acquisition coming from private channels [14][15]. - The company has a structured approach to doctor training and team building, ensuring high-quality service delivery [35]. Challenges and Future Outlook - Xinyang faces challenges in standardizing offerings due to the high skill requirements for personalized aesthetic services. The company is addressing this by focusing on easily standardized projects [13]. - The company is optimistic about achieving profitability in Q4 2025, despite current losses due to heavy investments in chain business development [25][36]. Conclusion - Xinyang is strategically positioned in the rapidly growing light medical beauty market in China, with a clear expansion plan, operational efficiencies, and a focus on product development. The company is well-equipped to navigate competitive pressures and capitalize on market opportunities.

Summary of the Conference Call on New Oxygen and the Medical Aesthetic Industry Industry Overview - The medical aesthetic industry experienced rapid growth from 2019 to 2022 but has faced challenges due to upstream price wars and weak downstream consumer demand in recent years. However, in 2025, there are signs of weak recovery with structural opportunities and innovative models emerging [2][4]. Company Insights - New Oxygen, a pioneer in the medical aesthetic e-commerce sector, once held an 86% market share in the medical aesthetic app market. The company was founded in 2013 and went public on NASDAQ in 2019 [2][4]. - The company has faced increased competition from internet platforms, leading to rising customer acquisition costs, which have negatively impacted revenue and profit [2][4]. Strategic Initiatives - New Oxygen is seeking to reverse its fortunes by expanding its supply chain and entering the downstream medical aesthetic institution operation sector. This includes acquiring companies like Qizhi Laser and becoming the exclusive agent for high-end products like Ellastin [1][5]. - As of mid-2025, New Oxygen has opened 32 stores under the New Oxygen Youth Clinic brand, generating total revenue of 170 million yuan [1][5]. Business Model and Performance - The New Oxygen Youth Clinic has a profitable model, with L Mall stores generating monthly revenues of 4 to 5 million yuan. The sales expense ratio is lower than traditional medical aesthetic clinics, resulting in a net profit margin superior to traditional retail [1][7]. - The clinic's customer retention is strong, with a 60% repurchase rate, a 50% referral rate, and 15% of traffic coming from organic sources [1][8]. Future Plans - New Oxygen plans to expand the number of clinics to 50 by the end of 2025, with 18 new stores expected to open in the second half of the year [1][8]. Quality Assurance and Transparency - New Oxygen ensures service quality and price transparency by tracing the qualifications of medical staff and maintaining a transparent pricing system. Prices for similar products in their clinics are at least 30% to 40% lower than market rates [1][10]. Standardization in the Industry - The medical aesthetic industry can achieve standardization, particularly in the light medical aesthetic sector, through a structured approach. New Oxygen employs a tiered management system for doctors and simplifies its product offerings to enhance standardization [11][12]. Challenges for Smaller Clinics - Smaller light medical aesthetic clinics face challenges such as traditional retail models, high customer acquisition costs, and difficulties in negotiating with suppliers. New Oxygen addresses these challenges by focusing on a light asset model and leveraging its established brand to drive traffic [14]. Conclusion - New Oxygen is positioned to capitalize on the recovery of the medical aesthetic industry through strategic expansions, a focus on quality and transparency, and a robust business model that leverages its brand equity and operational efficiencies [1][2][5][8][10].

Group 1 - The stock price of New Oxygen surged by 41.88% on Monday, reaching $1.66 per share and a market capitalization of $166 million, following a previous increase of 15.84% [1] - New Oxygen's stock had been underperforming since its NASDAQ debut in May 2019, where it initially rose by 31.88% to a market cap of approximately $1.823 billion [1] - Analysts attribute the recent stock surge to strong growth in the company's chain business, while advertising and upstream businesses remain undervalued [1] Group 2 - Founded in 2013, New Oxygen initially focused on an internet medical beauty platform, achieving rapid revenue growth from 49 million RMB in 2016 to 617 million RMB in 2018, with a compound annual growth rate of 254.85% [2] - The company has faced significant challenges in recent years due to competition from platforms like Alibaba Health and Meituan, as well as content e-commerce platforms like Douyin and Xiaohongshu [2] - New Oxygen plans to launch a new light medical beauty chain brand "New Oxygen Youth Clinic" in November 2024, aiming to reduce costs through centralized procurement and improve service efficiency [2] Group 3 - As of March 31, 2025, New Oxygen operates 23 medical beauty centers across nine major cities in China, with 18 centers achieving positive monthly cash flow [2] - The company reported a significant increase in quarterly write-off projects, exceeding 92,900, and a growth in quarterly paid users by 874% to over 45,500 [2] - Active user numbers surpassed 75,700, reflecting an 846% year-on-year increase, indicating enhanced user engagement [2] Group 4 - New Oxygen has recently been involved in disputes regarding its "Miracle Youth" project, which offers a product at a significantly lower price than the official price set by the manufacturer [3] - The company defends its product authenticity and compliance, while accusing competitors of unfair practices [3]